journal article·2024-04-17Open access

Enhanced Solubility and Bioavailability of Clotrimazole in Aqueous Solutions with Hydrophobized Hyperbranched Polyglycidol for Improved Antifungal Activity

Daria Jaworska-Krych, Monika Gosecka, Mateusz Gosecki, Malgorzata Urbaniak, Katarzyna Dzitko, Anita Ciesielska, Ewelina Wielgus, Slawomir Kadlubowski, Marcin Kozanecki

ACS Applied Materials & Interfaces· Volume 16· Issue 15

Abstract

High Resolution Image Download MS PowerPoint Slide The poor solubility of clotrimazole in the aqueous medium and the uncontrolled removal of the drug-loaded suppository content limit its effectiveness in the treatment of vulvovaginal candidiasis. We present here the aqueous formulations of clotrimazole in the form of non-Newtonian structured fluids, i.e., Bingham plastic or pseudoplastic fluids constructed of hyperbranched polyglycidol, HbPGL, with a hydrophobized core with aryl groups such as phenyl or biphenyl. The amphiphilic constructs were obtained by the modification of linear units containing monohydroxyl groups with benzoyl chloride, phenyl isocyanate, and biphenyl isocyanate, while the terminal 1,2-diol groups in the shell were protected during the modification step, followed by their deprotection. The encapsulation of clotrimazole within internally hydrophobized HbPGLs using a solvent evaporation method followed by water addition resulted in structured fluids formation. Detailed Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses performed for aryl-HbPGLs with clotrimazole revealed the difference in drug compatibility among polymers. Clotrimazole in biphenyl-enriched HbPGL, unlike phenyl derivatives, was molecularly distributed in both the dry and the hydrated states, resulting in transparent formulations. The shear-thinning properties of the obtained fluid formulations make them injectable and thus suitable for the intravaginal application. Permeability tests performed with the usage of the Franz diffusion cell showed a 5-fold increase in the permeability constant of clotrimazole compared to drugs loaded in a commercially available disposable tablet and a 50-fold increase of permeability in comparison to the aqueous suspension of clotrimazole. Furthermore, the biphenyl-modified HbPGL-based drug liquid showed enhanced antifungal activity against both Candida albicans and Candida glabrata that was retained for up to 7 days, in contrast to the phenyl-HbPGL derivatives and the tablet. With their simple formulation, convenient clotrimazole/biphenyl-HbPGL formulation strategy, rheological properties, and enhanced antifungal properties, these systems are potential antifungal therapeutics for gynecological applications. This study points in the synthetic direction of improving the solubility of poorly water-soluble aryl-enriched pharmaceuticals.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Antimicrobial agents and applications · Crystallography and molecular interactions · Nonlinear Optical Materials Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Sienkiewicza 112, 90-363 Lodz, Poland

Department of Molecular Microbiology, Faculty of Biology and Environmental Protection, University of Lodz, Banacha 12/16, 90-237 Lodz, Poland

Institute of Applied Radiation Chemistry, Lodz University of Technology, Wroblewskiego 15, 93-590 Lodz, Poland

Department of Molecular Physics, Faculty of Chemistry, Lodz University of Technology, Zeromskiego 116, 90-924 Lodz, Poland

Funding

Narodowe Centrum Nauki

References (38)

Show source-provided references
1. 10.1016/s0301-2115(00)00289-x10.1016/s0301-2115(00)00289-x ↗
2. 10.3389/fcimb.2023.112302610.3389/fcimb.2023.1123026 ↗
3. 10.3390/jof708066710.3390/jof7080667 ↗
4. 10.1007/s10096-013-2009-310.1007/s10096-013-2009-3 ↗
5. 10.1186/s40001-019-0399-010.1186/s40001-019-0399-0 ↗
6. 10.3390/ijms2311589510.3390/ijms23115895 ↗
7. 10.3109/10837450.2015.104104110.3109/10837450.2015.1041041 ↗
8. 10.3390/md1812059110.3390/md18120591 ↗
9. 10.1016/j.molliq.2018.02.06810.1016/j.molliq.2018.02.068 ↗
10. 10.1016/j.ijpharm.2020.11986710.1016/j.ijpharm.2020.119867 ↗
11. 10.4103/IJAM.IJAM_44_1910.4103/IJAM.IJAM_44_19 ↗
12. 10.1073/pnas.221794811910.1073/pnas.2217948119 ↗
13. 10.1007/s11908-022-00782-510.1007/s11908-022-00782-5 ↗
14. 10.1016/j.jiph.2022.08.00410.1016/j.jiph.2022.08.004 ↗
15. 10.1002/adfm.20221230210.1002/adfm.202212302 ↗
16. 10.1248/cpb.c14-0020210.1248/cpb.c14-00202 ↗
17. 10.1039/D1TB00263E10.1039/D1TB00263E ↗
18. 10.1007/s12247-018-9335-z10.1007/s12247-018-9335-z ↗
19. 10.1016/j.msec.2017.05.03010.1016/j.msec.2017.05.030 ↗
20. 10.31351/vol23iss1pp19-2510.31351/vol23iss1pp19-25 ↗
21. 10.3390/ijms2216838610.3390/ijms22168386 ↗
22. 10.1021/acs.biomac.2c0069110.1021/acs.biomac.2c00691 ↗
23. 10.1039/D2TB02629E10.1039/D2TB02629E ↗
24. Macosko C. W. · 1994
25. 10.1016/0260-8774(94)00010-710.1016/0260-8774(94)00010-7 ↗
26. 10.1007/s13367-015-0024-x10.1007/s13367-015-0024-x ↗
27. 10.1016/j.carbpol.2015.06.03210.1016/j.carbpol.2015.06.032 ↗
28. 10.1021/acs.chemrev.5b0048410.1021/acs.chemrev.5b00484 ↗
29. 10.1039/C5CE02385H10.1039/C5CE02385H ↗
30. 10.1021/ma961035f10.1021/ma961035f ↗
31. 10.1515/epoly-2016-015410.1515/epoly-2016-0154 ↗
32. 10.1021/la701600610.1021/la7016006 ↗
33. 10.1016/j.polymer.2020.12297410.1016/j.polymer.2020.122974 ↗
34. 10.1021/cr990050q10.1021/cr990050q ↗
35. 10.1002/cphc.20040024310.1002/cphc.200400243 ↗
36. 10.1007/s11746-016-2894-610.1007/s11746-016-2894-6 ↗
37. 10.1039/c5ra26218f10.1039/c5ra26218f ↗
38. 10.1016/j.ajog.2010.07.01010.1016/j.ajog.2010.07.010 ↗